Mind Medicine Australia FREE Webinar: Ask Me Anything = Everything you ever wanted to know about Psychedelic-Assisted Therapies with Professor David Nutt (UK)
Event description
Don’t miss out - Get your tickets early!
Join this FREE WEBINAR presented by Professor David Nutt (UK).
TOPIC: Ask Me Anything = Everything you ever wanted to know about Psychedelic-Assisted Therapies
A wonderful opportunity to learn about how and why these therapies work from one of the world’s leading researchers, Professor David Nutt from Imperial College London. David will also talk about the way forward for clinicians, researchers and those seeking these treatments.
There will be plenty of time for Q & A and you can ask David anything.
EVENT DETAILS
- DATE: 12th June 2024
- TIME: 5:55pm (AEST) for 6:00pm start, finishing at 7:15pm
- DURATION: 75 minutes (incl Q&A)
- LOCATION: Online - a link will be emailed to you with the viewing details
ABOUT THE PRESENTER
Professor David Nutt (UK)
Head of Neuropsychopharmacology at Imperial College London and the Chair of Drug Science.
Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London and the Chair of Drug Science.
Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.
Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.
He was previously Chair of the UK Advisory Council on the Misuse of Drugs.
---
MEDICINAL PSYCHEDELIC TREATMENTS
Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
SUPPORT PSYCHEDELIC RESEARCH AND THERAPY DEVELOPMENT
Your donation to Mind Medicine Australia will help us accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support. Please click here to make a tax-deductible donation.
DISCLAIMER
Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms i.e. Facebook, Instagram or zoom private and public chat forms during the webinar. Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters. Mind Medicine Australia is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for certain mental illnesses.